# Arbutus Biopharma (ABUS) — Earnings

ABUS · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/abus/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2025 |
| Period end | Jun 30, 2025 |
| EPS actual | $0.01 |
| EPS estimate | −$0.05 |
| EPS surprise | +121.05% |
| Revenue surprise | +574.98% |
| Revenue | $10.7M |
| Revenue estimate | $1.6M |
| Reported | Aug 6, 2025 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1447028/000144702825000115/abus-20250630.htm) |

Arbutus Biopharma's most recent quarter in the table is Q2 2025, reported August 6, 2025. EPS was $0.01, against an expected loss of $0.05, a 121.05% beat. Revenue was $10.7 million, far above the $1.6 million estimate, a 574.98% surprise. A year earlier, in Q2 2024, the company lost $0.11 per share on revenue of $1.7 million.

Q2 2025 was the only profitable quarter of the 20 shown; the other 19 were losses. The annual loss per share narrowed each year, from $0.83 in 2021 to $0.46 in 2022, $0.44 in 2023 and $0.38 in 2024. Revenue has moved unevenly, from a table high of $14.2 million in Q2 2022 to a low of $1.3 million in Q3 2024, with full-year revenue of $39.0 million in 2022 and $6.1 million in 2024. Arbutus beat EPS estimates in 11 of the 20 quarters.

The table has no quarter after Q2 2025. In earlier years, third-quarter results came between November 4 and November 9, and fourth-quarter results between late February and late March. The next quarter added here will show whether the Q2 2025 profit was repeated or stood as a single result.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2025 | Aug 6, 2025 | −$0.05 | $0.01 | 121.05% | $1.6M | $10.7M |
| Q1 2025 | May 14, 2025 | −$0.10 | −$0.13 | -25.00% | $1.6M | $1.8M |
| Q4 2024 | Mar 27, 2025 | −$0.08 | −$0.07 | 12.50% | $1.6M | $1.6M |
| Q3 2024 | Nov 6, 2024 | −$0.09 | −$0.10 | -6.38% | $1.9M | $1.3M |
| Q2 2024 | Aug 1, 2024 | −$0.10 | −$0.11 | -14.58% | $1.8M | $1.7M |
| Q1 2024 | May 2, 2024 | −$0.11 | −$0.10 | 9.09% | $2.7M | $1.5M |
| Q4 2023 | Feb 29, 2024 | −$0.12 | −$0.12 | -3.45% | $4.8M | $2.1M |
| Q3 2023 | Nov 7, 2023 | −$0.11 | −$0.12 | -7.14% | $4.8M | $4.7M |
| Q2 2023 | Aug 3, 2023 | −$0.11 | −$0.10 | 10.71% | $6.2M | $4.7M |
| Q1 2023 | May 4, 2023 | −$0.14 | −$0.10 | 26.47% | $6.0M | $6.7M |
| Q4 2022 | Mar 2, 2023 | −$0.13 | −$0.13 | 2.99% | $6.2M | $6.2M |
| Q3 2022 | Nov 9, 2022 | −$0.13 | −$0.12 | 6.25% | $9.4M | $6.0M |
| Q2 2022 | Aug 4, 2022 | −$0.12 | −$0.10 | 19.35% | $6.8M | $14.2M |
| Q1 2022 | May 5, 2022 | −$0.16 | −$0.11 | 31.25% | $4.4M | $12.6M |
| Q4 2021 | Mar 3, 2022 | −$0.19 | −$0.15 | 21.05% | $2.9M | $3.2M |
| Q3 2021 | Nov 4, 2021 | −$0.24 | −$0.24 | -0.84% | $2.4M | $3.3M |
| Q2 2021 | Aug 5, 2021 | −$0.23 | −$0.23 | -2.22% | $2.1M | $2.3M |
| Q1 2021 | May 5, 2021 | −$0.23 | −$0.21 | 9.25% | $3.3M | $2.1M |
| Q4 2020 | Mar 4, 2021 | −$0.22 | −$0.23 | -3.88% | $2.0M | $2.4M |
| Q3 2020 | Nov 5, 2020 | −$0.22 | −$0.27 | -25.00% | $1.7M | $1.5M |

## Frequently Asked Questions

### When did Arbutus Biopharma (ABUS) last report earnings?

Arbutus Biopharma last reported on Aug 6, 2025, covering fiscal Q2 2025.

### Did ABUS beat earnings estimates?

Yes. Arbutus Biopharma reported EPS of $0.01 for Q2 2025 against a −$0.05 estimate — a 121.05% beat.

### How much revenue did ABUS report last quarter?

Arbutus Biopharma reported $10.7M in revenue for Q2 2025, against a consensus estimate of $1.6M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).